In consultation: Guidance and quality standards
Showing 1 to 4 of 4
Title | Consultation | Type | Consultation end date |
---|---|---|---|
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] | Draft guidance | Technology appraisal guidance | |
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] | Draft guidance | Technology appraisal guidance | |
Targeted muscle reinnervation for managing limb amputation pain | Interventional procedure consultation | Interventional procedures guidance | |
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] | Draft guidance | Technology appraisal guidance |